Moving away from the generic treatment for all cancer, precision medicine provides a targeted therapy based on the different profile presented. Since the signing of Precision Medicine Initiative by the then US President Barack Obama in 2015, the research on precision medicine increased exponentially. Tumor can have only one, or a combination of different, disease-causing factor, including aberrant production of proteins or cell receptors, or mutated genes. By using biomarkers, doctors are able to identify specific cause of the tumor or predict outcome of a particular therapy. Such biomarkers include tumor antigens, such as neoantigens and cancer testis antigens, PD-L1, receptor tyrosine kinases, and tumor mutational burden. Detection of these biomarkers can be done with techniques such as ELISA, PCR, FISH, or IHC, depending on the nature of biomarker. With the rise of artificial intelligence, this technology has been applied to automate the process of detection, diagnosis, and tumor grading.